TET2-AS1

Across TCGA pan-cancer cohorts, TET2-AS1 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TET2-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TET2-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types TET2-AS1 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

HNSC, LIHC, and STAD are the cancer types where TET2-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TET2-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	−0.292	.014	5	view →
LIHC	All	All	+0.113	.004	5	view →
STAD	Female	All	+0.400	.036	2	view →
BRCA	Female	All	+0.181	.029	2	view →
LUSC	Male	All	+0.097	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

TET2-AS1–HNSC

Open the HNSC breakdown →